Covance Inc (CVD.N)

CVD.N on New York Stock Exchange

94.44USD
23 Apr 2014
Price Change (% chg)

$-0.25 (-0.26%)
Prev Close
$94.69
Open
$94.87
Day's High
$94.87
Day's Low
$94.26
Volume
5,370
Avg. Vol
103,187
52-wk High
$106.49
52-wk Low
$71.90

CVD.N

Chart for CVD.N

About

Covance Inc. is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. The Company also provides laboratory testing services to the chemical, agrochemical and food... (more)

Overall

Beta: 0.90
Market Cap (Mil.): $5,422.72
Shares Outstanding (Mil.): 57.27
Dividend: --
Yield (%): --

Financials

  CVD.N Industry Sector
P/E (TTM): 30.04 26.72 33.26
EPS (TTM): 3.15 -- --
ROI: 10.76 -2.48 18.95
ROE: 12.48 -11.48 19.72
Search Stocks

CORRECTED-MARKET PULSE-3D Systems, Cognizant, Estee Lauder, Pernix Therapeutics

(Corrects 3D Systems item to say the company cut its adjusted profit forecast for the full year, not fourth quarter) U.S. stocks fell on Wednesday, following a report on the private labor market that was weaker than expected, though investors were also looking ahead to impending data on the services sector. The Dow Jones industrial average was down 0.29 percent at 15,400.42, the S&P 500 was down 0.48 percent at 1,746.82 and the Nasdaq Composite was down 0.71 percent at 4,002.954.

05 Feb 2014

Late-stage drug research powers Covance profit beat

- Research services provider Covance Inc reported a better-than-expected 19 percent jump in quarterly adjusted profit as it gained from higher investments in later stages of drug development by pharma companies.

04 Feb 2014

Covance profit beats estimates as late-stage drug trials shine

Feb 4 - Research services provider Covance Inc reported a better-than-expected 19 percent jump in quarterly adjusted profit as it gained from higher investments in later stages of drug development by pharma companies.

04 Feb 2014

BRIEF-Neogenomics to collaborate with Covance to jointly provide testing services for clinical trials

Nov 18 - Neogenomics Inc : * To collaborate with Covance to jointly provide anatomic pathology and

18 Nov 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks